Opinion|Videos|September 19, 2024

Outcomes of Class Switching vs Cycling TNF Inhibitors

Panelists discuss how switching to a biologic with a different mechanism of action can enhance clinical outcomes in patients with inadequate responses to tumor necrosis factor inhibitors.

Episodes in this series

Video content above is prompted by the following:

  • What outcomes are associated with switching to a biologic with a different mechanism of action (MOA) rather than cycling a tumor necrosis factor inhibitor (TNFi)?
  • Can you describe an anecdotal patient case in which the patient switched therapy to a different MOA? Did the switch happen after a few TNFis or after first TNFi

Related Content